Trade Delcath Systems, Inc. - DCTH CFD

Trading Conditions

• Spread: 0.04
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 5.44
• Open: 5.28
• 1-Year Change: -8.33%
• Day's Range: 5.05 - 5.32

Delcath Systems, Inc. Company profile

About Delcath Systems Inc

Delcath Systems, Inc. is an oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company is a specialty pharmaceutical and medical device company developing its products. The Company's lead product candidate is HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Delcath Systems Inc revenues increased 27% to $1.4M. Net loss applicable to common stockholders increased 18% to $20.3M. Revenues reflect Product revenue increase of 35% to $1.1M, Other revenue increase of 9% to $392K. Higher net loss reflects Research and development expenses increase from $3M to $8.3M (expense), Stock-based Compensation in SGA increase from $49K to $4.2M (expense), Selling.

Equity composition

Common Stock $.01 Par, 12/10, 70M auth., 43,028,146 issd., less 28,100 shares in Treas. @ $51.1M. Insiders control 1.42%. InitialPublic Offering 10/20/00, 1.2M Units (1 Common+ 1Redeemable Warrant) @ $6 by Whale Securities Co . 5/20/03,Company sold 677,419 Units (5 Common + 5 Warrants) @ $3.10/unit. 98.3. 04/14, 1-for-16 Reverse stock split.